Company Supernus Pharmaceuticals, Inc.

SUPN

US8684591089

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 11:34:16 2025-06-13 EDT			5-day change	1st Jan Change
32.78 ^USD	+0.05%		-1.10%	-9.33%

05-28	Supernus Pharmaceuticals, Inc. Announces Paragraph IV ANDA Filings for Qelbree®?	CI
05-06	Supernus Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 06, 2025

Business description: Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinsonâs Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Number of employees: 674

Sales by Activity: Supernus Pharmaceuticals, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
Pharmaceuticals	520M	580M	667M	608M	662M

See all business segments

Geographical breakdown of sales: Supernus Pharmaceuticals, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
United States	520M	580M	667M	608M	662M

See all geographic segments

Executive Committee: Supernus Pharmaceuticals, Inc.

Manager	Title	Age	Since
Jack Khattar CEO	Chief Executive Officer	63	2005-12-21
Timothy Dec DFI	Director of Finance/CFO	66	2021-08-22
Kevin T. Anderson CMP	Compliance Officer	62	2011-12-31
Jonathan Rubin CTO	Chief Tech/Sci/R&D Officer	63	2020-12-31
Frank Mottola CTO	Chief Tech/Sci/R&D Officer	53	2016-12-31

See SUPERNUS PHARMACEUTICALS, INC. governance

Composition of the Board of Directors: Supernus Pharmaceuticals, Inc.

Director	Title	Age	Since
Jack Khattar BRD	Director/Board Member	63	2005-12-21
Charles Newhall CHM	Chairman	79	2016-08-09
Frederick Hudson BRD	Director/Board Member	79	2010-11-15
Georges Gemayel BRD	Director/Board Member	64	2015-03-22
Carrolee Barlow BRD	Director/Board Member	61	2018-06-26
Bethany Sensenig BRD	Director/Board Member	49	2023-08-20

Composition of the Board of Directors

Shareholders: Supernus Pharmaceuticals, Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 16.28 %	9,085,636	16.28 %	288 M $
Vanguard Fiduciary Trust Co. 11.04 %	6,163,892	11.04 %	195 M $
Armistice Capital LLC 9.309 %	5,196,000	9.309 %	165 M $
DFA Australia Ltd. 5.017 %	2,800,112	5.017 %	89 M $
Macquarie Investment Management Business Trust 4.837 %	2,699,667	4.837 %	86 M $

List of SUPERNUS PHARMACEUTICALS, INC. shareholders

Company details: Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc.

9715 Key West Avenue

20850, Rockville

+301 838 2500

http://www.supernus.com

address Supernus Pharmaceuticals, Inc.(SUPN)

Specialty & Advanced Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SUPERNUS PHARMACEUTICALS, INC.	+0.05%	-1.10%	+23.44%	+23.67%	1.83B
MERCK KGAA	-1.50%	-0.39%	-33.40%	-31.53%	58.6B
KYOWA KIRIN CO., LTD.	0.00%	+0.99%	-7.56%	-15.32%	9.07B
HALOZYME THERAPEUTICS, INC.	-0.53%	+0.07%	+9.41%	+25.96%	6.72B
YUHAN CORPORATION	-1.75%	+2.60%	+43.34%	+105.27%	5.96B
SK BIOPHARMACEUTICALS CO., LTD.	-3.42%	-0.11%	+13.16%	+11.48%	5.4B
BETTA PHARMACEUTICALS CO., LTD.	-1.97%	+2.13%	+65.40%	+24.96%	3.79B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	-1.55%	+0.74%	-1.37%	+19.40%	2.06B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-3.26%	-7.06%	-62.78%	-7.65%	1.82B
INDIVIOR PLC	+0.44%	+0.59%	-19.92%	-27.95%	1.73B
Average	-1.36%	-0.57%	+2.97%	+12.83%	9.7B
Weighted average by Cap.	-1.41%	+0.37%	-15.40%	-10.39%